Candel Financial Statements From 2010 to 2026

CADL Stock  USD 5.55  0.12  2.12%   
Candel Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Candel Therapeutics' valuation are provided below:
Gross Profit
-23.1 M
Market Capitalization
311.3 M
Enterprise Value Revenue
821.9774
Revenue
31 K
Earnings Share
(0.56)
There are over one hundred nineteen available fundamental signals for Candel Therapeutics, which can be analyzed over time and compared to other ratios. We recommend to validate Candel Therapeutics' prevailing fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 259.8 M this year. Enterprise Value is expected to rise to about 175.5 M this year
Check Candel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Candel Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 1.2 M, Depreciation And Amortization of 1.2 M or Interest Expense of 2.5 M, as well as many indicators such as Price To Sales Ratio of 451, Dividend Yield of 0.0 or PTB Ratio of 3.92. Candel financial statements analysis is a perfect complement when working with Candel Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Candel Stock
Check out the analysis of Candel Therapeutics Correlation against competitors.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.

Candel Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets73.3 M122.9 M59.4 M
Slightly volatile
Short and Long Term Debt Total11.2 M15.5 M5.4 M
Slightly volatile
Other Current Liabilities32.4 M30.9 MM
Slightly volatile
Total Current Liabilities45.3 M43.2 M10 M
Slightly volatile
Other Liabilities2.2 M2.3 MM
Very volatile
Property Plant And Equipment Net3.5 M3.1 M1.8 M
Slightly volatile
Accounts Payable202.6 K213.3 K361.5 K
Pretty Stable
Cash60.7 M118.1 M32.7 M
Slightly volatile
Non Current Assets Total4.1 M3.5 M2.1 M
Slightly volatile
Non Currrent Assets Other369.6 K378.4 K303.4 K
Slightly volatile
Other Assets358.9 K305.9 K288 K
Slightly volatile
Long Term Debt2.8 MM2.8 M
Slightly volatile
Cash And Short Term Investments68 M118.1 M56.6 M
Slightly volatile
Common Stock Total Equity189.9 K328.9 K172.9 K
Slightly volatile
Common Stock Shares Outstanding28.5 M36.4 M22.9 M
Slightly volatile
Liabilities And Stockholders Equity73.3 M122.9 M59.4 M
Slightly volatile
Non Current Liabilities Total2.6 M2.7 M38.2 M
Slightly volatile
Other Current Assets1.3 M1.3 M644 K
Slightly volatile
Total Liabilities32.1 M36.5 M46.7 M
Slightly volatile
Property Plant And Equipment Gross4.8 M6.7 M2.4 M
Slightly volatile
Total Current Assets69.3 M119.4 M57.3 M
Slightly volatile
Capital Stock287.3 K539.4 K202.2 K
Slightly volatile
Net Working Capital56.7 M76.2 M49.2 M
Slightly volatile
Common Stock287.3 K539.4 K202.2 K
Slightly volatile
Property Plant Equipment3.4 M6.3 M2.2 M
Slightly volatile
Current Deferred Revenue123.1 K129.6 K2.1 M
Slightly volatile
Deferred Long Term Liabilities537.4 KM356.1 K
Slightly volatile
Short and Long Term Debt7.1 M11.4 M3.5 M
Slightly volatile
Short Term Debt12.6 M12 MM
Slightly volatile
Long Term Debt Total448 K504 K550.1 K
Slightly volatile
Capital Surpluse115.3 M129.7 M141.6 M
Slightly volatile
Non Current Liabilities Other14.6 M16.4 M17.9 M
Slightly volatile

Candel Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1.2 M1.2 M1.1 M
Pretty Stable
Depreciation And Amortization1.2 M1.1 M342.1 K
Slightly volatile
Interest Expense2.5 M2.4 M1.2 M
Slightly volatile
Selling General Administrative11 M16.2 M6.4 M
Slightly volatile
Selling And Marketing Expenses768.1 K790 K444.8 K
Slightly volatile
Other Operating Expenses28.3 M38.4 M17.9 M
Slightly volatile
Research Development17.4 M22.2 M11.4 M
Slightly volatile
Cost Of Revenue1.1 M1.1 M5.6 M
Pretty Stable
Total Operating Expenses22.7 M37.2 M12.2 M
Slightly volatile
Reconciled Depreciation1.2 M1.1 M340.4 K
Slightly volatile

Candel Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation6.4 M6.1 M1.9 M
Slightly volatile
Begin Period Cash Flow46.6 M41 M33 M
Slightly volatile
Depreciation626.5 K1.1 M327.6 K
Slightly volatile
Capital Expenditures13.7 K14.4 K394.1 K
Pretty Stable
End Period Cash Flow61 M118.4 M33 M
Slightly volatile
Cash And Cash Equivalents Changes38.2 M43 M46.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio451475911
Slightly volatile
Stock Based Compensation To Revenue12.4416.619.234
Slightly volatile
Capex To Depreciation0.01770.01863.7236
Pretty Stable
EV To Sales37.939.89717
Slightly volatile
Payables Turnover3.573.7622.0173
Slightly volatile
Sales General And Administrative To Revenue51.9510148.3442
Slightly volatile
Research And Ddevelopement To Revenue82.1215085.3349
Slightly volatile
Capex To Revenue7.629.345.1351
Slightly volatile
Cash Per Share1.872.922.3832
Very volatile
Days Payables Outstanding95.46100327
Pretty Stable
Income Quality0.640.440.6797
Pretty Stable
Net Debt To EBITDA2.071.971.2021
Slightly volatile
Current Ratio3.023.1821.6653
Slightly volatile
Capex Per Share6.0E-46.0E-40.0171
Pretty Stable
Revenue Per Share0.00610.0050.006
Slightly volatile
Interest Debt Per Share0.30.440.1872
Slightly volatile
Debt To Assets0.140.110.0791
Slightly volatile
Days Of Payables Outstanding95.46100327
Pretty Stable
Ebt Per Ebit0.91.491.0221
Slightly volatile
Quick Ratio3.023.1821.6653
Slightly volatile
Net Income Per E B T0.170.180.7523
Slightly volatile
Cash Ratio2.993.154.9076
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.171.151.0546
Slightly volatile
Fixed Asset Turnover0.02490.02620.1846
Slightly volatile
Debt Ratio0.140.110.0791
Slightly volatile
Price Sales Ratio451475911
Slightly volatile
Asset Turnover0.00250.00190.0024
Slightly volatile

Candel Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap259.8 M247.4 M209.9 M
Pretty Stable
Enterprise Value175.5 M167.2 M133.5 M
Pretty Stable

Candel Fundamental Market Drivers

Forward Price Earnings43.4783
Cash And Short Term Investments102.7 M

Candel Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Candel Therapeutics Financial Statements

Candel Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Candel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue129.6 K123.1 K
Cost Of Revenue1.1 M1.1 M
Stock Based Compensation To Revenue 16.61  12.44 
Sales General And Administrative To Revenue 101.23  51.95 
Research And Ddevelopement To Revenue 149.67  82.12 
Capex To Revenue 9.34  7.62 
Revenue Per Share 0.00  0.01 
Ebit Per Revenue(319.44)(335.41)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
Check out the analysis of Candel Therapeutics Correlation against competitors.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.56)
Revenue Per Share
0.001
Return On Assets
(0.43)
Return On Equity
(0.70)
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.